

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32498C1	PRED. APPLN. NO. 10/168,872
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Robin Edward Buckingham	
		PRED. FILING DATE 04 October 2002	PRED. GROUP 1614

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<i>Ca</i>	CA	Shimoyama, et al., "Hemodynamic Basis for the Acute Cardiac Effects of Troglitazone in Isolated Perfused Rat Hearts", <i>Diabetes</i> , 48(3): 609-615 (1999).
<i>Co</i>	CB	Dagogo-Jack, et al., "Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Inventions", <i>Arch. Int. Med.</i> , 157(16): 1802-1817 (1997).
<i>He</i>	CC	Hosokawa, et al., "Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum", <i>J. Pharmacol. Exp. Ther.</i> , 290(3): 1080-1084 (1999).

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.